+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Repatha"

From
From
Hypercholesterolaemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypercholesterolaemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Cardiovascular Calcification - Pipeline Insight, 2025 - Product Thumbnail Image

Cardiovascular Calcification - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
From
From
Cardiovascular Drugs: Global Markets to 2022 - Product Thumbnail Image

Cardiovascular Drugs: Global Markets to 2022

  • Report
  • March 2018
  • 174 Pages
  • Global
From
From
From
From
From
From
  • 16 Results (Page 1 of 1)
Loading Indicator

Repatha is a cardiovascular drug used to reduce the risk of heart attack and stroke in adults with certain conditions. It is a monoclonal antibody that works by blocking a protein called PCSK9, which helps regulate the amount of cholesterol in the blood. Repatha is used in combination with diet and exercise to reduce the risk of cardiovascular events in adults with established cardiovascular disease, or those at high risk of cardiovascular events due to familial hypercholesterolemia. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and atherosclerotic cardiovascular disease. The Repatha market is highly competitive, with several major pharmaceutical companies offering the drug. These include Amgen, Sanofi, Regeneron, and Pfizer. Other companies, such as Merck, are also developing PCSK9 inhibitors, which could potentially compete with Repatha in the future. Show Less Read more